Long-term, open-label, multicenter study assessing long-term cardiovascular risks in patients treated with fingolimod
Phase of Trial: Phase IV
Latest Information Update: 23 Oct 2019
Price : $35 *
At a glance
- Drugs Fingolimod (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Novartis
- 16 Apr 2015 Planned number of patients changed from 200 to 40, according to to ClinicalTrials.gov record.
- 16 Apr 2015 Status changed from not yet recruiting to recruiting, according to to ClinicalTrials.gov record.
- 11 Sep 2014 Planned End Date changed from 30 May 2020 to 1 Jul 2020.